

## Dear State Surveyor:

This report is designed to provide a comparative summary of treatment patterns and patient outcomes for End Stage Renal Disease (ESRD) patients in this state, as compared to all patients in the United States. The statistics reported here include dialysis patients treated during 2021-2024 in the chronic dialysis facilities in this state and are based primarily on data from the ESRD Quality Reporting System (EQRS), Medicare claims, and data collected for CMS. Selected statistics from this profile are summarized below and state-to-state comparisons of key statistics are provided in the *Maps and Tables of Key Statistics by State*.

## ESRD CORE Pre-Survey Data Tool

For each facility with CCN xxxxxx in your state, key data elements from the DFR reviewed in the Core Survey Pre-survey Preparation task are reported in the QDFR\_FY26\_SEP\_UPDATE\_xxxxxx.pdf available on the secure Dialysis Reports website ([www.DialysisData.org](http://www.DialysisData.org)).

Selected highlights for this State are provided on the first few pages. For a complete description of the methods and data reported here please see the *Guide to the State Profiles for FY 2026*. The Guide is available on the Dialysis Data website at [www.DialysisData.org](http://www.DialysisData.org). We hope this profile is of interest to you and is helpful in your survey efforts. We welcome your feedback on ways to improve future profiles.

## What's New This Year

As part of a continuing effort to improve the quality and relevance of this report for your state, the following change has been incorporated into the State Profile for FY 2026: the Prevalent Standardized Waitlist Ratio (PSWR) was added to Table 5. This measure is similar to the Standardized Waitlist Ratio in the First Year (FySWR), but includes all eligible patients and includes time to all waitlists as opposed to just the first event. The PSWR improves reporting of access to transplantation for prevalent patients compared to the age-adjusted percentage of patient-months waitlisted reported in row 5m, given the focus on time to waitlisting (as opposed to percentage waitlisted in a year), and also includes more robust risk adjustments (similar to the FySWR with the inclusion of patient vintage).

## State Highlights

**Patient Characteristics:** On December 31<sup>st</sup>, 2024, 12.1% of patients in this state were treated in a nursing home during the year, compared to 13.3% nationally. See **Table 1** for detailed summaries of all patients treated during 2021-2024 in this state.

Form CMS-2728 collected data from 2,173 incident patients in this state in 2024. **Table 2** describes certain important characteristics of these patients at the time of their first outpatient dialysis session, including patients' demographics, medical coverage, primary cause of ESRD, modality, pre-treatment nephrological care, transplant options, and vascular access type. In 2024, the average age of patients in this state at incidence was 63 years, compared to the national average of 63 years. Asian patients made up 11% of the patients in this state compared to 6% nationally. Among the incident patients in this state in 2024, 91.0% were informed of their transplant options, compared to 93.5% nationally. Also in 2024, 16.8% of incident patients in this state were not under the care of a nephrologist prior to ESRD therapy, compared to 15.7% nationally.

**Mortality:** There were 1,506 deaths among the patients treated in this state during 2024, while 1,517 would be expected based on their age, race, ethnicity, sex, diabetes status, duration of ESRD, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.98, which is 2% lower than expected. Of the deaths in this state in 2024, 27% were preceded by withdrawal from dialysis, compared to the national average of 23%. See **Table 3** of this profile for more detailed mortality statistics during 2021-2024 in this state.

**First Year Mortality:** There were 351 deaths among the incident patients treated in this state during 2023, while 351 would be expected based on their age, race, ethnicity, sex, diabetes status, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The First Year Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.99, which is 1% lower than expected. Of the deaths among incident patients in this state in 2023, 27% were preceded by withdrawal from dialysis, compared to the national average of 24%. See **Table 3** of this profile for more detailed first year mortality statistics during 2021-2023 in this state.

**Hospitalization:** The Standardized Hospitalization Ratio (SHR) of observed to expected hospital admissions for patients in this state during 2024 is 0.91, indicating that these patients had 9% fewer admissions than expected based on characteristics of patients treated in this state. The Standardized Readmission Ratio (SRR) of observed to expected hospital readmissions in this state during 2024 is 0.99, indicating that these patients had 1% fewer readmissions than expected. See **Table 4** of this profile for additional hospitalization statistics during 2021-2024 in this state.

**Transplantation:** 337 patients under age 75 in this state during 2024 received their first transplant, while 334 would be expected based on the age of these patients. The Standardized Transplantation Ratio (STR) of observed to expected number of patients transplanted for this state is 1.01, which is 1% higher than expected. See **Table 5** of this profile for additional transplantation statistics during 2021-2024 in this state.

**Kidney Transplant Waitlist for Prevalent Patients:** The 2024 age-adjusted percent waitlisted in this state is 14.7%, which is 1.6% lower than the national adjusted percentage. See **Table 5** of this profile for additional transplant waitlist statistics during 2021-2024 in this state.

**Kidney Transplant Waitlist for Incident Patients:** The 2023 first-year Standardized Waitlist Ratio (FySWR) in this state is 0.91, which is 9% fewer patients waitlisted or living donor transplants than expected in this state. See **Table 5** of this profile for additional transplant waitlist statistics during 2021-2023 in this state.

**Influenza Vaccination:** On December 31, 2024, 77% of all patients treated in this state were vaccinated against influenza between August 1 and December 31, 2024, compared to 78% nationally. This difference is statistically significant ( $p < 0.05$ ) and is unlikely to be due to random chance. See **Table 6** of this profile for more information about vaccinated patients during 2021-2024 in this state.

**Anemia Management:** In 2024, 22.8% of eligible hemodialysis patient-months in this state had a hemoglobin value below 10 g/dL, compared to 23.3% nationally. In 2024, 20.9% of eligible peritoneal dialysis patient-months had a hemoglobin value below 10 g/dL, compared to 22.6% nationally. See **Table 7** of this profile for additional anemia management statistics in this state during 2021-2024.

**Dialysis Adequacy:** Of the eligible hemodialysis patient-months in this state in 2024, 97% had a Kt/V  $\geq 1.2$ , compared to 97% nationally. Of the eligible peritoneal dialysis patient-months in this state in 2024, 93% had a Kt/V  $\geq 1.7$ , compared to 92% nationally. See **Table 8** of this profile for more information on dialysis during 2021-2024 in this state.

**Mineral Metabolism:** In 2024, 17% of eligible patient-months in this state had a serum phosphorus value  $>7.0$  mg/dL, compared to 17% nationally. Also in 2024, 1.3% of eligible patient-months in this state had a calcium uncorrected value  $>10.2$  mg/dL, compared to 1.1% nationally. See **Table 9** of this profile for more mineral metabolism summaries in this state during 2021-2024.

**Vascular Access:** In 2024, 13% of the incident hemodialysis patients in this state had an arteriovenous (AV) fistula in use, compared to 12% in the nation. This state's 2024 Standardized Fistula Rate (SFR) for prevalent patients is 58%, which is 0% higher than the national SFR. Of the prevalent patients receiving hemodialysis treatment in this state, the long-term catheter rate was 19%, compared to 18% nationally. See **Table 10** of this profile for additional information about vascular access in this state during 2021-2024.

SAMPLE

State Profile for FY 2026 for Dialysis Patients and Facilities  
STATE SAMPLE

The tables below provide updates of COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients (Table C1) and Medicare nursing home (NH) dialysis patients (Table C2), 2021-2024. National averages for 2024 are reported for comparison.

**TABLE C1. COVID among Medicare Dialysis Patients, 2021-2024<sup>\*1</sup>**

Outcome Description		This State				United States
		2021	2022	2023	2024	2024
1	Medicare dialysis patients (n)	9,622	9,252	9,138	9,135	n/a
2	Patients ever infected with COVID (n)	1,816	2,548	2,366	2,083	n/a
	Patients ever infected with COVID (% of 1)	17.4	27.3	25.7	22.7	22.8
3	Patients initially infected with COVID (n)	993	1,250	465	309	n/a
	Patients initially infected with COVID (% of 1)	9.6	13.8	5.1	3.4	3.4
<b>Deaths among Medicare patients</b>						
4	Deaths (n)	1,549	1,440	1,336	1,333	n/a
5	Deaths among patients ever infected with COVID (n)	441	513	450	409	n/a
	Deaths among patients ever infected with COVID (% of 4)	24.6	35.2	33.2	29.9	30.6
<b>Hospitalizations<sup>*2</sup> among Medicare patients</b>						
6	Hospitalizations (n)	5,511	5,355	5,305	5,242	n/a
7	Hospitalizations among patients ever infected with COVID (n)	1,353	1,820	1,617	1,385	n/a
	Hospitalizations among patients ever infected with COVID (% of 6)	22.4	33.6	30.3	26.5	26.4

**TABLE C2. COVID among Medicare Dialysis Patients Treated in Nursing Home (NH) Facilities, 2021-2024<sup>\*1</sup>**

Outcome Description		This State				United States
		2021	2022	2023	2024	2024
1	Medicare NH dialysis patients (n)	1,667	1,625	1,648	1,694	n/a
2	Patients ever infected with COVID (n)	541	669	605	536	n/a
	Patients ever infected with COVID (% of 1)	30.4	40.3	36.5	30.8	31.7
3	Patients initially infected with COVID (n)	264	340	148	107	n/a
	Patients initially infected with COVID (% of 1)	14.5	21.5	9.0	6.3	6.4
<b>Deaths among Medicare NH patients</b>						
4	Deaths (n)	497	479	471	481	n/a
5	Deaths among patients ever infected with COVID (n)	175	210	189	174	n/a
	Deaths among patients ever infected with COVID (% of 4)	33.5	45.9	39.6	34.9	36.1
<b>Hospitalizations<sup>*2</sup> among Medicare NH patients</b>						
6	Hospitalizations (n)	1,409	1,377	1,398	1,408	n/a
7	Hospitalizations among patients ever infected with COVID (n)	458	580	523	451	n/a
	Hospitalizations among patients ever infected with COVID (% of 6)	30.9	41.3	37.6	31.5	32.0

[\*1] Includes patients with Medicare as primary insurer or with a Medicare Advantage plan. Table C2 includes patients who were treated in a nursing home at least one day during the year. See *Guide, Section XVII*.

[\*2] Hospitalization is defined as having at least one day in a hospital from Medicare inpatient claims during the reporting period.

State Profile for FY 2026 for Dialysis Patients and Facilities  
STATE SAMPLE

**TABLE 1: Summaries for All Dialysis Patients Treated as of December 31<sup>st</sup> of each Year, 2021-2024<sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	2024
1a	Patients treated on 12/31 of year (n)	8,624	8,522	8,547	8,517	476,949
1b	Average age (years)	62.2	62.2	62.3	62.5	62.6
1c	Age (% of 1a; sums to 100%)					
	< 18	0.2	0.2	0.2	0.2	0.2
	18-64	52.2	51.7	51.4	50.9	50.6
	65+	47.6	48.0	48.4	48.9	49.2
1d	Female (% of 1a)	42.2	42.0	41.9	42.1	41.8
1e	Race (% of 1a; sums to 100%)					
	African American	28.4	28.5	28.4	28.3	34.2
	Asian/Pacific Islander	11.1	11.1	11.2	11.3	7.1
	Native American	3.3	3.4	3.6	3.6	1.3
	White	56.7	56.3	55.9	55.2	55.7
	Other/Unknown/Missing	0.5	0.6	0.9	1.5	1.8
1f	Ethnicity (% of 1a; sums to 100%)					
	Hispanic	13.9	14.5	14.9	15.3	24.1
	Non-Hispanic	86.0	85.5	85.1	84.7	75.9
	Unknown	0.0	0.0	0.0	0.0	0.0
1g	Cause of ESRD (% of 1a; sums to 100%)					
	Diabetes	47.3	46.7	46.4	45.9	44.4
	Hypertension	26.5	26.7	27.0	27.3	31.1
	Glomerulonephritis	10.5	10.2	9.9	9.7	8.5
	Other/Unknown	15.5	16.1	16.4	16.8	15.7
	Missing	0.2	0.3	0.3	0.3	0.3
1h	Average duration of ESRD (years)	4.9	4.9	4.9	4.9	5.0
1i	Years since start of ESRD (% of 1a; sums to 100%)					
	<1	16.8	16.5	16.5	16.6	16.3
	1-2	17.1	18.0	17.6	17.6	17.3
	2-3	14.2	13.7	14.3	13.9	13.8
	3-6	25.7	25.9	25.7	26.0	26.2
	6+	26.2	25.8	25.9	25.8	26.3
1j	Nursing facility patients <sup>*2</sup> (% of 1a)	11.8	11.6	11.9	12.1	13.3
1k	Modality (% of 1a; sums to 100%)					
	In-center hemodialysis	84.5	83.9	83.5	83.2	83.3
	Home hemodialysis	3.0	3.2	3.6	4.0	3.8
	Continuous ambulatory peritoneal dialysis	1.4	1.5	1.6	1.8	1.5
	Continuous cycling peritoneal dialysis	10.6	10.9	10.9	10.7	11.0
	Other modality	0.5	0.5	0.4	0.4	0.3

n/a = not applicable.

[\*1] See *Guide, Section IV* for detailed information regarding the summaries included in Table 1.

[\*2] Includes patients who were treated at a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset.

State Profile for FY 2026 for Dialysis Patients and Facilities  
STATE SAMPLE

**TABLE 2: Characteristics of New Dialysis Patients, 2021-2024 (Form CMS-2728) <sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	
<b>Patient Characteristics</b>						<b>2024</b>
2a	Total number of patients with forms (n)	2,268	2,184	2,182	2,173	121,685
2b	Age (average years [0-95]) <sup>*2</sup>	62.5	62.4	62.7	62.8	63.0
2c	Female (% of 2a)	41.6	41.9	41.2	42.2	41.5
2d	Race (% of 2a; sums to 100%)					
	African American	23.5	23.7	23.3	23.0	27.8
	Asian/Pacific Islander	10.7	10.7	10.8	10.8	6.4
	Native American	3.0	3.0	3.3	3.0	1.2
	White	62.3	61.3	60.7	59.3	59.9
	Other/Unknown/Missing	0.6	1.3	1.9	3.9	4.8
2e	Hispanic (% of 2a)	13.0	13.4	13.3	14.1	21.6
2f	Primary cause of ESRD (% of 2a; sums to 100%)					
	Diabetes	48.1	47.4	47.4	46.5	43.4
	Hypertension	26.1	26.7	27.2	26.7	31.7
	Glomerulonephritis	7.1	7.3	6.8	6.7	5.7
	Other/Missing	18.7	18.6	18.6	20.1	19.2
2g	Medical Coverage (% of 2a; sums to 100%)					
	Employer group only	12.0	12.1	11.3	11.7	11.5
	Medicare only	41.2	42.9	43.0	39.4	40.6
	Medicaid only	17.0	16.0	16.6	16.9	15.3
	Medicare and Medicaid only	7.0	7.1	8.0	9.2	9.1
	Medicare and Other	9.4	9.5	9.9	11.0	9.6
	Other/Unknown	9.8	9.0	8.1	8.5	10.0
	None	3.6	3.4	3.2	3.3	4.0
2h	Body Mass Index					
	Male	28.5	28.1	27.9	27.8	27.6
	Female	29.4	28.9	28.9	28.6	28.4
2i	Employment (% of 2a)					
	Six months prior to ESRD treatment	35.0	37.8	38.7	37.4	36.8
	At first ESRD treatment	26.2	29.0	30.4	27.4	25.9
2j	Primary Modality (% of 2a; sums to 100%)					
	Hemodialysis	87.2	86.1	85.6	86.3	86.1
	CAPD/CCPD	12.8	13.9	14.4	13.7	13.9
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.0
2k	Number of incident hemodialysis patients (n)	1,965	1,869	1,858	1,872	104,821
2l	Access used at first outpatient dialysis (% of 2k; sums to 100%)					
	Arteriovenous fistula	13.4	13.8	14.3	14.2	13.0
	Arteriovenous graft	2.5	2.9	2.7	2.9	3.0
	Catheter	83.7	83.0	82.6	82.5	83.5
	Other/Unknown/Missing	0.3	0.3	0.3	0.4	0.5
2m	Arteriovenous fistulae placed (% of 2k) <sup>*3</sup>	24.7	23.8	24.2	23.7	21.6
<b>Average Lab Values Prior to Dialysis <sup>*2</sup></b>						
2n	Hemoglobin (g/dL [5-20])	9.3	9.3	9.3	9.4	9.4
2o	Serum Albumin (g/dL [0.8-6.0])	3.4	3.4	3.4	3.4	3.5
2p	Serum Creatinine (mg/dL [0-33])	6.7	6.7	6.6	6.5	6.4
2q	GFR (ml/min [0-30])	9.7	9.7	9.8	9.9	10.0

(continued)

State Profile for FY 2026 for Dialysis Patients and Facilities  
STATE SAMPLE

**TABLE 2 (continued): Characteristics of New Dialysis Patients, 2021-2024 (Form CMS-2728) <sup>\*1</sup>**

		This State				United States
Measure Name		2021	2022	2023	2024	
Care Prior to ESRD Therapy						
2r	Received ESA prior to ESRD (% of 2a)	16.9	17.1	17.2	18.0	17.4
2s	Pre-ESRD nephrologist care (% of 2a; sums to 100%)					
	No	18.3	17.0	16.7	16.8	15.7
	Yes, <6 months	16.9	18.0	18.4	17.5	19.0
	Yes, 6-12 months	19.0	18.4	18.0	18.4	18.5
	Yes, >12 months	32.6	32.7	32.6	33.2	29.0
	Unknown	13.2	13.8	14.3	13.9	17.6
2t	Informed of transplant options (% of 2a)	88.5	89.7	90.4	91.0	93.5
2u	Patients not informed of transplant options (n)	202	160	153	136	7,621
2v	Reason not informed (% of 2u; may not sum to 100%)					
	Medically unfit	35.7	39.4	40.8	25.0	25.2
	Unsuitable due to age	0.0	0.0	0.0	0.2	0.1
	Psychologically unfit	0.0	0.0	0.0	0.0	0.0
	Patient declined information	7.1	10.0	9.4	3.1	3.2
	Patient has not been assessed	50.9	54.7	54.6	33.5	34.9
Comorbid Conditions						
2w	Pre-existing Comorbidity (% yes of 2a)					
	Congestive heart failure	27.8	26.3	26.1	27.7	27.7
	Atherosclerotic heart disease	12.6	11.9	12.3	18.6	19.3
	Other cardiac disorder	20.4	19.8	20.7	24.9	25.3
	CVD, CVA, TIA	8.2	8.5	7.9	9.1	9.8
	Peripheral vascular disease	9.2	8.2	8.0	10.2	9.6
	History of hypertension	87.2	86.5	87.1	88.3	89.1
	Diabetes	64.5	64.1	64.5	64.5	63.7
	Diabetes on insulin	42.4	40.9	41.7	41.4	41.0
	COPD	8.3	7.9	7.8	8.5	8.2
	Current smoker	7.4	7.3	7.7	8.3	7.7
	Cancer	6.7	6.4	6.6	8.5	8.3
	Alcohol dependence	2.0	2.0	2.0	2.5	2.3
	Drug dependence	1.7	1.8	1.9	2.4	2.5
	Inability to ambulate	5.8	5.9	5.6	8.4	9.3
	Inability to transfer	2.8	3.0	2.7	4.6	5.7
2x	Average number of comorbid conditions	3.1	3.0	3.0	3.3	3.3
	Standardized Modality Switch Ratio (SMoSR)	2021	2022	2023		2023
2y	Eligible patients (n)	2,103	2,005	1,961		109,911
2z	Patient-years at risk (n)	1,482	1,417	1,403		78,661
2aa	Number of modality switches (n)	188	180	177		9,915
2ab	Expected number of modality switches (n)	189	180	177		9,923
2ac	SMoSR (2aa/2ab) *A	1.07	1.13	1.09		1.00

n/a= not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section V* for detailed information regarding the summaries included in Table 2.

[\*2] For continuous variables, all summaries are computed based only on responses in range indicated in brackets for the variable.

[\*3] Includes all patients with AV fistulae, regardless of whether they recieved their hemodialysis treatments using their fistulae.

**TABLE 3: Mortality Summary for All Dialysis Patients (2021-2024) & New Dialysis Patients (2021-2023)**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	
<b>All Patients: Standardized Mortality Ratio (SMR)</b>						<b>2024</b>
3a	Patients (n)	12,235	12,097	12,029	11,972	740,533
3b	Patient-years at risk (n)	8,711	8,558	8,546	8,556	491,294
3c	Deaths (n)	1,739	1,616	1,508	1,506	90,212
3d	Expected deaths (n)	1,852	1,684	1,531	1,517	87,435
3e	Withdrawal from dialysis prior to death (% of 3c)	24.7	26.8	26.9	27.4	22.7
3f	Deaths due to infections (% of 3c)	11.2	10.5	10.0	9.7	9.0
3g	Deaths due to cardiac causes (% of 3c)	42.4	42.9	44.6	44.3	45.1
3h	Deaths due to liver disease (% of 3c)	1.4	1.3	1.3	1.5	1.2
3i	Dialysis unrelated deaths (n; excluded from SMR)	10	11	10	9	541
3j	SMR (3c /3d ) <sup>*A, *2</sup>	0.91	0.96	0.97	0.98	1.03
3k	P-value <sup>*B</sup>	0.149	.	.	.	n/a
<b>New Patients: First-Year Standardized Mortality Ratio (FySMR)</b>						<b>2023</b>
3l	Patients (n)	2,268	2,184	2,182		122,171
3m	Patient-years at risk (n)	2,019	1,959	1,958		109,633
3n	Deaths (n)	403	358	351		19,668
3o	Expected deaths (n)	404	356	351		19,641
3p	Withdrawal from dialysis prior to death (% of 3n)	26.9	27.2	27.2		23.6
3q	Deaths due to infections (% of 3n)	10.9	9.8	9.4		8.8
3r	Deaths due to cardiac causes (% of 3n)	39.1	38.8	39.2		40.1
3s	Deaths due to liver disease (% of 3n)	2.3	2.7	2.4		2.0
3t	FySMR (3n /3o ) <sup>*A, *2</sup>	1.02	1.01	0.99		1.00
3u	P-value <sup>*B</sup>		.	.		n/a

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section VI* for detailed information regarding the summaries included in Table 3.

[\*2] The SMRs (3j, 3t) are not shown if there are fewer than 3 expected deaths (3d,3o).



**TABLE 4: Hospitalization Summary for Medicare Dialysis Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Medicare Dialysis Patients</b>						
4a	Medicare dialysis patients (n)	9,836	9,535	9,455	9,415	576,905
4b	Patient-years at risk (n)	6,746	6,574	6,567	6,534	372,253
<b>Standardized Hospitalization Ratio (SHR) for Days Hospitalized</b> <sup>*2</sup>						
4c	Total days hospitalized (n)	74,709	74,903	73,454	73,250	4,430,847
4d	Expected days hospitalized (n)	78,933	79,052	77,256	76,585	4,397,920
4e	SHR for Days (4c/4d) <sup>*A</sup>	0.89	0.89	0.89	0.90	1.00
4f	P-value for SHR (Days) <sup>*B</sup>	0.068	0.064	0.057	0.066	n/a
<b>Standardized Hospitalization Ratio (SHR) for Hospital Admissions</b> <sup>*2, *3</sup>						
4g	Total admissions (n)	9,113	8,723	9,221	9,426	550,886
4h	Expected total admissions (n)	9,243	8,879	9,400	9,605	550,867
4i	SHR for Admissions (4g/4h) <sup>*A</sup>	0.93	0.91	0.90	0.91	1.00
4j	P-value for SHR (Admissions) <sup>*B</sup>	0.106	0.090	0.127	0.125	n/a
4k	Patients with septicemia (% of 4a)	11.6	11.9	11.9	12.0	12.3
4l	One day admissions (% of 4g)	8.8	8.5	8.7	8.0	7.8
4m	Average length of stay (days per admission)	7.8	8.1	7.8	7.7	8.0
4n	Admissions that originate in the ED (% of 4g)	79.2	80.5	81.2	82.0	84.6
<b>Standardized Emergency Department Encounter Ratio (SEDR)</b> <sup>*2</sup>						
4o	Emergency department (ED) events (n)	5,235	4,474	3,951	3,612	207,466
4p	Expected number of emergency department events (n)	5,272	4,528	4,021	3,665	208,897
4q	SEDR (4o/4p) <sup>*A</sup>	1.09	1.08	1.04	1.05	0.99
4r	P-value for SEDR <sup>*B</sup>	0.098	0.104	0.131	0.142	n/a
<b>Standardized Ratio of ED Encounters Occurring within 30 Days of Hospital Discharge (ED30)</b>						
4s	Index discharges (n)	4,371	3,746	3,454	3,218	180,215
4t	Total ED visits within 30 days of hospital discharge (n)	644	535	487	452	25,294
4u	Expected total ED visits within 30 days of hospital discharge (n)	596	491	442	405	22,673
4v	ED30 Ratio (4t/4u) <sup>*A</sup>	1.20	1.22	1.26	1.23	1.12
<b>Standardized Readmission Ratio (SRR)</b> <sup>*2</sup>						
4x	Index discharges (n)	8,391	8,168	8,392	8,465	474,064
4y	Total readmissions (n)	2,200	2,125	2,211	2,302	128,907
4z	Expected total readmissions (n)	2,130	2,038	2,124	2,233	125,047
4aa	SRR (4y/4z) <sup>*A</sup>	0.99	1.00	1.01	0.99	1.03

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section VII* for detailed information regarding the summaries included in Table 4. SEDR and ED30 statistics include only patients with Medicare as primary insurer and exclude patients with Medicare Advantage plans. All other summaries include patients with Medicare as primary insurer or with a Medicare Advantage plan.

[\*2] SHRs and SEDR are not shown if there are less than five patient-years at risk. SRR and ED30 ratios are not shown if fewer than 11 index discharges in the year.

[\*3] Rows 4g-4j exclude index COVID hospitalizations, while rows 4l-4n include all admissions. Row 4k includes diagnoses in any position on a hospital inpatient claim.

**TABLE 5: Transplantation and Waitlist Summary for All Dialysis Patients (2021-2024) & New Dialysis Patients (2021-2023) under Age 75<sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	
<b>Transplantation: All Transplants</b>						<b>2024</b>
5a	Eligible patients (n)	9,789	9,618	9,488	9,367	580,300
5b	Transplants (n)	351	357	374	375	21,194
<b>Transplantation: First Transplants</b>						
5c	Eligible patients (n)	9,156	8,997	8,878	8,771	540,737
5d	Patient-years at risk (n)	6,541	6,383	6,323	6,282	360,771
5e	Actual first transplants (n)	314	322	334	337	19,023
5f	Expected first transplants (n)	306	316	329	334	19,181
5g	Standardized Transplantation Ratio (STR; 5e/5f)	0.99	0.99	0.97	1.01	0.99
5h	P-value <sup>*B</sup>	.	.	.	.	n/a
<b>Dialysis Patients on the Waitlist</b>						
5i	Eligible patients (n)	9,641	9,432	9,256	9,107	510,003
5j	Patient-months at risk (n) <sup>*3</sup>	82,055	79,883	79,048	78,038	4,370,133
5k	Patient-months on the waitlist (% of 5j) <sup>*3</sup>	15.3	15.2	14.9	14.9	16.5
5l	Patient-months on the waitlist by subgroup (%) <sup>*C, *2</sup>					
	Age < 40	23.6	23.5	23.1	23.7	25.8
	Age 40-74	14.4	14.2	13.9	13.9	15.5
	Male	16.3	16.2	15.9	15.9	17.7
	Female	13.9	13.7	13.4	13.4	14.7
	African American	15.6	16.0	14.9	14.8	15.3
	Asian/Pacific Islander	22.4	22.6	21.2	20.8	24.0
	Native American	11.4	10.5	10.8	12.1	9.6
	White, Hispanic	15.4	15.3	17.0	15.4	16.7
	White, Non-Hispanic	16.2	15.5	15.4	16.1	16.5
	Other/Unknown race	13.3	14.3	14.9	15.6	15.7
	Diabetes	12.2	12.4	12.5	12.5	14.1
	Non-diabetes	18.0	17.6	16.9	16.8	18.5
	Previous kidney transplant	27.1	27.1	26.1	25.6	28.2
	No previous kidney transplant	14.4	14.3	14.1	14.1	15.7
	<2 years since start of ESRD	12.7	12.8	13.0	13.3	13.6
	2-4 years since start of ESRD	19.3	19.3	19.0	19.0	21.1
	5+ years since start of ESRD	14.4	14.0	13.1	12.7	15.5
5m	Age-adjusted percentage of patient-months waitlisted	15.1	14.9	14.6	14.7	16.2
5n	Patient-months on the waitlist in active status (% of 5j) <sup>*C</sup>	9.0	8.5	8.4	8.4	9.8
5o	Age-adjusted % of patient-months waitlisted in active status	8.8	8.2	8.2	8.2	9.6
<b>All Patients: Prevalent Standardized Waitlist Ratio (PSWR)</b>						
5p	Eligible patients (n)	7,840	7,344	6,990	6,722	415,011
5q	Patient-years at risk (n)	5,731	5,251	5,020	4,847	279,114
5r	Waitlist events (n) <sup>*3</sup>	380	385	396	417	23,329
5s	Expected waitlist events (n) <sup>*3</sup>	375	382	391	413	23,138
5t	PSWR (5r/5s) <sup>*A, *3</sup>	1.01	0.94	0.96	0.97	1.01
5u	P-value for PSWR <sup>*B</sup>	.	0.102	.	.	n/a

(continued)

**TABLE 5 (continued): Transplantation and Waitlist Summary for All Dialysis Patients (2021-2024) & New Dialysis Patients (2021-2023) under Age 75<sup>\*1</sup>**

Measure Name		This State			United States
		2021	2022	2023	
<b>New Dialysis Patients: First-Year Standardized Waitlist Ratio (FySWR)</b>					<b>2023</b>
5v	Eligible Patients (n)	1,522	1,452	1,428	79,960
5w	Patient-years at risk (n)	1,356	1,303	1,281	71,719
5x	First waitlist events (n) <sup>*3</sup>	131	130	133	7,432
5y	Expected first waitlist events (n) <sup>*3</sup>	123	129	141	7,914
5z	FySWR (5x/5y) <sup>*A, *3</sup>	1.12	1.01	0.91	0.93
5aa	P-value for FySWR <sup>*B</sup>	0.131	.	0.146	n/a

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide Section VIII* for detailed information regarding the transplant and waitlist summaries included in Table 5. Eligible patient-months (5j) include patients assigned to the facility on the last day of each month.

[\*2] The waitlist percentage for each subgroup is calculated as a rate of waitlisted patient-months to patient-months at risk in each subgroup. A missing value indicates that there were no eligible patients in the subgroup.

[\*3] An event is defined as a waitlisting or living-donor transplant. FySWR and PSWR are not shown if a facility has less than 2 expected waitlisted events or less than 11 eligible patients.

State Profile for FY 2026 for Dialysis Patients and Facilities  
STATE SAMPLE

**TABLE 6: Influenza Vaccination Summary All Dialysis Patients, Flu Seasons during August 2021-December 2024<sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	
						<b>2024</b>
6a	Eligible patients on 12/31 (n)	9,139	9,033	9,041	9,019	505,089
6b	Patients excluded due to medical contraindication (n)	99	225	173	180	10,091
<b>Full Flu Season (Aug. 1-Mar. 31 of following year)</b>						<b>2023</b>
6c	Patients vaccinated (% of 6a)	82.5	82.1	80.4		79.9
6d	P-value <sup>*2</sup> (for 6c compared to U.S. value <sup>*3</sup> )	0.047	0.039	0.034		n/a
6e	Reason for no vaccination (% of 6a)					
	Declined vaccination	7.8	7.3	8.3		8.5
	Other reason or vaccine data not available	8.9	10.6	11.3		11.5
<b>Half Flu Season (Aug. 1-Dec. 31)</b>						<b>2024</b>
6f	Patients vaccinated (% of 6a)	80.2	79.9	77.9	77.0	78.0
6g	P-value <sup>*2</sup> (for 6f compared to U.S. value <sup>*4</sup> )	0.042	0.042	0.016	0.034	n/a
6h	Patients vaccinated by subgroup (%) <sup>*5</sup>					
	Medicare	81.1	80.8	78.9	78.0	79.1
	Medicare Advantage	83.0	81.5	79.6	79.6	80.2
	Medicare as primary insurer	80.5	80.0	78.0	77.1	77.7
	Non-Medicare	74.6	74.0	71.4	70.8	72.8
	Dual Medicare/Medicaid eligible	79.3	79.7	77.8	76.4	77.6
	Age < 18	73.4	65.2	63.4	64.8	62.9
	Age 18-39	70.6	70.8	68.1	66.3	67.2
	Age 40-64	78.7	78.0	75.3	74.4	75.0
	Age 65-74	82.3	81.9	80.4	78.8	80.5
	Age 75+	84.4	84.2	82.4	82.4	83.9
	Male	80.1	79.5	77.0	76.0	77.1
	Female	80.4	80.5	78.9	78.1	78.9
	African American	79.1	79.1	74.6	76.2	74.1
	Asian/Pacific Islander	84.5	84.2	83.0	82.6	84.5
	Native American	82.0	80.7	78.1	77.7	82.1
	White	82.5	81.1	78.8	77.8	79.4
	Other/unknown race	74.6	73.0	71.1	76.4	74.7
	Hispanic	81.8	83.3	79.3	80.2	82.0
	< 1 year since start of ESRD	73.6	72.0	70.4	70.0	70.2
	1-2 years since start of ESRD	80.9	79.9	77.3	76.0	76.7
	3+ years since start of ESRD	82.7	83.4	81.3	80.4	81.7

n/a = not applicable

[\*1] See *Guide, Section X* for detailed information regarding the summaries included in Table 6. All Dialysis Patients are those treated on December 31<sup>st</sup> of the reporting year.

[\*2] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the state and national percentage is plausibly due to random chance.

[\*3] Compared to the U.S. value for that year and time period (08/01-03/31): 83% (2021), 82% (2022), 80% (2023).

[\*4] Compared to the U.S. value for that year and time period (08/01-12/31): 81% (2021), 81% (2022), 79% (2023), 78% (2024).

[\*5] A missing value indicates that there were no eligible patients in the subgroup.

**TABLE 7: Anemia Management Summaries for Adult Dialysis Patients, 2021-2024<sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Hemoglobin and ESA for Adult Hemodialysis (HD) Patients</b>						
7a	Eligible HD patients (n)	9,516	9,322	9,259	9,242	510,185
7b	Eligible HD patient-months (n) <sup>*C</sup>	88,321	86,402	86,180	85,930	4,812,059
7c	Average hemoglobin (g/dL) (average of 7b)	10.7	10.7	10.8	10.7	10.7
7d	Hemoglobin categories (% of 7b; sums to 100%)					
	<10 g/dL	22.4	23.1	22.8	22.8	23.3
	10-<11 g/dL	33.6	33.4	32.4	32.7	33.2
	11-12 g/dL	27.9	27.6	28.7	28.6	29.6
	>12 g/dL	12.6	12.2	12.9	12.8	12.6
	Missing/Out of range	3.7	3.7	3.2	3.0	1.3
7e	ESA prescribed (% of 7b)	73.3	73.5	74.0	74.3	77.6
<b>Hemoglobin and ESA for Adult Peritoneal Dialysis (PD) Patients</b>						
7f	Eligible PD patients (n)	1,492	1,495	1,512	1,496	82,768
7g	Eligible PD patient-months (n) <sup>*C</sup>	11,925	11,951	12,130	12,209	683,685
7h	Average hemoglobin (g/dL) (average of 7g)	11.0	11.0	11.0	11.0	11.0
7i	Hemoglobin categories (% of 7g; sums to 100%)					
	<10 g/dL	20.7	21.0	20.8	20.9	22.6
	10-<11 g/dL	27.3	27.2	26.4	27.1	28.0
	11-12 g/dL	26.0	25.8	26.6	26.6	26.7
	>12 g/dL	20.6	20.7	21.8	21.3	20.2
	Missing/Out of range	5.4	5.2	4.4	4.1	2.5
7j	ESA prescribed (% of 7g)	52.7	52.2	52.1	52.2	55.1
<b>Standardized Transfusion Ratio (STrR)</b>						
7k	Adult Medicare patients (n)	5,042	4,250	3,807	3,542	212,388
7l	Patient-years at risk (n)	2,955	2,489	2,191	1,976	112,000
7m	Total transfusions (n)	1,000	796	693	610	36,453
7n	Expected total transfusions (n)	1,034	833	726	642	36,486
7o	STrR(7m/7n) <sup>*A, *1</sup>	0.94	0.92	0.92	0.91	0.99
7p	P-value <sup>*B</sup>	0.119	0.161	0.147	0.123	n/a

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XI* for detailed information regarding the summaries included in Table 7. Transfusion summaries include adult Medicare dialysis patients only and not shown if there are fewer than 10 patient-years at risk (7o).

**TABLE 8: Dialysis Adequacy Summaries for All Dialysis Patients, 2021-2024<sup>\*1</sup>**

		This State				United States
Measure Name		2021	2022	2023	2024	2024
<b>Adult Hemodialysis (HD) Adequacy</b>						
8a	Eligible HD patients (n)	9,516	9,322	9,259	9,242	510,185
8b	Eligible HD patient-months (n) <sup>*C</sup>	88,321	86,402	86,180	85,930	4,812,059
8c	Average serum albumin (g/dL) (average of 8b)	3.9	3.9	3.9	3.9	3.9
8d	Serum albumin categories (% of 8b; sums to 100%)					
	< 3.0 g/dL	2.3	2.0	1.8	1.8	1.7
	3.0-<3.5 g/dL	9.4	8.5	8.1	8.2	7.9
	3.5-<4.0 g/dL	39.2	38.7	40.3	40.4	40.2
	>=4.0 g/dL	46.1	47.5	47.3	47.4	48.0
	Missing	3.1	3.4	2.6	2.3	2.1
8e	Ultrafiltration rate average (ml/kg/hr) (average of 8b)	7.7	7.7	7.7	7.6	7.6
8f	Ultrafiltration rate categories (% of 8b; sums to 100%)					
	<=13 (ml/kg/hr)	86.8	86.5	86.8	87.6	87.9
	>13 (ml/kg/hr)	7.6	7.8	7.7	7.3	7.5
	Out of Range (>=20 ml/kg/hr)	2.3	2.4	2.5	2.5	2.3
	Missing	3.3	3.3	3.0	2.6	2.3
8g	Eligible HD Kt/V patients (n) <sup>*2</sup>	9,039	8,855	8,775	8,720	481,560
8h	Eligible HD Kt/V patient-months (n) <sup>*C, *2</sup>	82,569	80,805	80,539	79,843	4,471,189
8i	Average Kt/V (average of 8h) <sup>*2</sup>	1.6	1.6	1.6	1.6	1.6
8j	Kt/V categories (% of 8h; sums to 100%) <sup>*2</sup>					
	<1.2	1.8	1.9	1.6	1.7	1.6
	1.2-<1.8	71.2	71.7	69.8	72.0	72.0
	>=1.8	25.4	24.7	27.1	25.0	25.1
	Missing/Out of range	1.6	1.8	1.5	1.3	1.3
<b>Adult Peritoneal Dialysis (PD) Adequacy</b>						
8k	Eligible PD patients (n)	1,492	1,495	1,512	1,496	82,768
8l	Eligible PD patient-months (n) <sup>*C</sup>	11,925	11,951	12,130	12,209	683,685
8m	Average Weekly Kt/V (average of 8l) <sup>*2</sup>	2.2	2.2	2.2	2.2	2.2
8n	Weekly Kt/V categories (% of 8l; sums to 100%) <sup>*2</sup>					
	<1.7	4.8	5.1	4.9	4.7	4.8
	1.7-<2.5	68.1	68.7	68.0	68.8	68.3
	>=2.5	23.6	23.3	24.5	24.0	24.0
	Missing/Out of range	3.5	2.9	2.6	2.5	2.9
8o	Average serum albumin (g/dL) (average of 8l)	3.7	3.7	3.7	3.7	3.7
8p	Serum Albumin Categories (% of 8l; sums to 100%)					
	< 3.0 g/dL	6.7	6.0	5.3	5.2	4.9
	3.0-<3.5 g/dL	22.4	21.1	20.3	20.7	20.5
	3.5-<4.0 g/dL	41.4	42.8	44.8	44.9	45.0
	>=4.0 g/dL	25.8	26.8	26.8	26.6	26.9
	Missing	3.7	3.3	2.8	2.6	2.7

(continued)

**TABLE 8 (continued): Dialysis Adequacy Summaries for All Dialysis Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Pediatric Kt/V</b> <sup>*2</sup>						
8q	Eligible Pediatric HD patients (n)	14	16	17	16	833
8r	Eligible Pediatric HD patient-months (n) <sup>*C</sup>	95	107	113	111	5,667
8s	Average Kt/V (average of 8r)	1.8	1.8	1.7	1.7	1.7
8t	Kt/V categories (% of 8r; sums to 100%)					
	<1.2	1.7	2.4	2.6	2.7	2.2
	1.2-<1.8	57.0	52.9	56.3	56.3	54.9
	>= 1.8	36.5	38.5	29.9	31.5	27.7
	Missing/Out of Range	4.8	6.2	11.2	9.4	15.2
8u	Eligible Pediatric PD Patients (n)	21	20	19	19	867
8v	Eligible Pediatric PD patient-months (n) <sup>*C</sup>	152	151	145	136	6,262
8w	Average Weekly Kt/V (average of 8v)	2.4	2.4	2.4	2.4	2.4
8x	Weekly Kt/V categories (% of 8v; sums to 100%)					
	<1.7	12.6	14.0	13.3	11.8	13.1
	1.7-<2.5	50.1	45.8	46.2	46.8	48.7
	>=2.5	30.1	27.1	30.7	31.4	30.3
	Missing/Out of Range	7.2	13.1	9.7	10.0	7.9

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XII* for detailed information regarding the summaries included in Table 8.

[\*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "*Determination of Thrice Weekly Dialysis*" for more information. The most recent value over a 4-month period is selected for PD Kt/V.

**TABLE 9: Mineral Metabolism Summaries for All Adult Dialysis Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	2024
9a	Eligible adult patients (n)	10,715	10,528	10,480	10,462	577,189
9b	Eligible adult patient-months (n) <sup>*C</sup>	100,502	98,608	98,552	98,373	5,508,873
9c	Average Phosphorus (mg/dL) <sup>*2</sup>	5.5	5.5	5.5	5.6	5.6
9d	Phosphorus categories (% of 9b; sums to 100%) <sup>*2</sup>					
	<3.5 mg/dL	6.8	7.4	7.3	7.0	7.1
	3.5-4.5 mg/dL	21.7	22.2	21.9	21.2	21.7
	4.6-5.5 mg/dL	28.1	27.4	26.8	26.4	27.1
	5.6-7.0 mg/dL	23.0	22.7	23.8	24.5	24.8
	>7.0 mg/dL	16.0	15.8	16.4	17.1	17.4
	Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0
	Missing	4.5	4.5	3.9	3.7	2.0
9e	Average Calcium Uncorrected (mg/dL)	8.9	8.9	8.9	8.9	8.9
9f	Calcium Uncorrected categories (% of 9b; sums to 100%)					
	<8.4 mg/dL	18.5	18.7	19.9	19.1	19.3
	8.4-10.2 mg/dL	76.8	76.8	76.3	77.2	77.8
	>10.2 mg/dL	1.3	1.2	1.1	1.3	1.1
	Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0
	Missing	3.3	3.3	2.7	2.4	1.8
9g	Average uncorrected calcium > 10.2 mg/dL (%) <sup>*3</sup>	2.6	2.4	2.0	1.9	1.2

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XIII* for detailed information regarding the summaries included in Table 9.

[\*2] Eligible patients included in the phosphorous summaries differ slightly from what is reported in 9b since it includes patient-months within the first 90 days of ESRD.

[\*3] Hypercalcemia is averaged from uncorrected serum or plasma calcium values over a rolling 3-month period. Eligible patients included in the hypercalcemia summary differs slightly from what is reported in 9b since patients must be 18 as of the first day of the 3-month period.



**TABLE 10: Vascular Access Information for all Adult Dialysis Patients and Access-Related Infection Summaries for all Medicare Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Vascular Access</b> <sup>*2</sup>						
10a	Prevalent adult hemodialysis (HD) patients (n)	10,028	9,811	9,697	9,673	533,945
10b	Prevalent adult hemodialysis patient months (n) <sup>*C</sup>	92,080	89,997	89,209	88,757	4,970,374
10c	Vascular access type in use (% of 10b; sums to 100%)					
	Arteriovenous fistula	61.4	60.3	59.8	58.8	58.6
	Arteriovenous graft	15.6	15.4	15.3	15.5	16.7
	Catheter	20.5	21.9	23.0	24.0	23.6
	Other/Missing	2.4	2.4	1.9	1.6	1.1
10d	Standardized Fistula Rate (SFR) <sup>*3</sup>	60.7	59.4	59.0	58.2	58.1
10e	Long-Term Catheter Rate <sup>*4</sup>	15.8	17.1	17.8	18.5	17.9
<b>Vascular Access at First Treatment</b>						
10f	Incident adult hemodialysis patients (n)	1,988	1,885	1,871	1,895	106,095
10g	Vascular access type in use (% of 10f; sums to 100%)					
	Arteriovenous fistula	13.3	13.5	13.8	13.4	12.3
	Arteriovenous graft	2.8	3.1	3.2	3.2	3.4
	Catheter	82.2	81.4	81.3	79.6	80.5
	Other/Missing	1.8	1.9	1.7	3.9	3.8
10h	Arteriovenous fistulae in placed (% of 10f) <sup>*5</sup>	14.3	14.4	14.7	14.1	12.8
<b>Infection: Peritoneal dialysis (PD)</b>						
10i	Eligible PD patients (n)	848	756	710	665	37,230
10j	Eligible PD patient-months (n) <sup>*C</sup>	5,872	5,261	4,901	4,601	257,634
10k	PD catheter infection rate per 100 PD patient-months	2.6	2.6	2.5	2.4	2.4
10l	P-value <sup>*6</sup> of 10k (compared to U.S. value <sup>*7</sup> )	0.127	0.162	0.165	0.161	n/a

n/a = not applicable

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XIV* for detailed information regarding the summaries included in Table 10.

[\*2] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded.

[\*3] Includes patients with an autogenous arteriovenous (AV) fistula as the sole means of vascular access. SFR is calculated as an adjusted rate of AV fistula in use reported in 10c.

[\*4] Includes patients using a catheter continuously for three months or longer. Patients with other or missing access types (10c) are also counted as catheter in use in the numerator.

[\*5] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

[\*6] A p-value greater than or equal to 0.05 indicates the differences between the percent of patients with infection at the facility and national percentage is plausibly due to random change.

[\*7] Compared to U.S. value for that year: 2.59 (2021), 2.47 (2022), 2.47 (2023), and 2.41 (2024).

**TABLE 11: Comorbidities Reported on Inpatient Medicare Claims for Medicare Dialysis Patients Treated as of December 31<sup>st</sup> of Each Year, 2021-2024<sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	2024
11a	Medicare dialysis patients on 12/31(n)	6,829	6,606	6,615	6,598	376,446
11b	Comorbidity (% yes of 11a)					
	<b>Infections</b>					
	AIDS/HIV positive	0.6	0.6	0.6	0.6	0.8
	Intravascular/implanted device-related <sup>*2</sup>	4.5	4.5	4.7	4.5	4.7
	Hepatitis B	0.4	0.4	0.4	0.4	0.4
	Hepatitis other	1.5	1.5	1.3	1.2	1.4
	Metastatic	1.3	1.4	1.6	1.6	1.6
	Pneumonia	2.9	3.3	3.5	3.6	3.9
	Tuberculosis	0.2	0.2	0.2	0.2	0.3
	Other	16.8	17.4	17.9	18.0	19.1
	<b>Cardiovascular</b>					
	Cardiac arrest	0.9	0.8	0.9	0.8	0.9
	Cardiac dysrhythmia	17.6	18.0	18.6	18.9	19.9
	Cerebrovascular disease	6.3	6.4	6.7	6.9	8.0
	Congestive heart failure	27.9	28.9	29.9	30.1	32.4
	Ischemic heart disease	23.9	24.3	24.5	24.6	26.7
	Myocardial infarction	7.2	7.5	7.8	8.1	8.8
	Peripheral vascular disease <sup>*3</sup>	15.1	15.0	15.5	15.6	17.8
	<b>Other</b>					
	Alcohol dependence	1.4	1.5	1.5	1.5	1.5
	Anemia	2.7	3.0	3.0	3.1	3.4
	Cancer	3.1	3.3	3.4	3.5	3.8
	Chronic obstructive pulmonary disease	13.4	13.8	14.0	14.4	14.9
	Diabetes	34.3	34.8	35.4	34.9	37.1
	Drug dependence	1.2	1.2	1.3	1.3	1.3
	Gastrointestinal tract bleeding	2.7	2.7	2.8	2.9	3.3
	Hyperparathyroidism	18.6	19.6	20.7	21.2	22.2
11c	Average number of comorbid conditions	2.0	2.1	2.2	2.2	2.3

n/a = not applicable.

[\*1] See *Guide, Section XV* for detailed information regarding the summaries included in Table 11. Based on patients with Medicare as primary insurer on 12/31 each year.

[\*2] This category includes bloodstream and other infections related to intravascular access and other implanted devices, not limited to dialysis access.

[\*3] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases.

**TABLE 12: Selected Summaries for Nursing Home (NH) Patients, 2021-2024<sup>\*1</sup>**

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Patient Characteristics</b>						
12.1a	Patients treated on 12/31 (n)	1,089	1,081	1,111	1,131	63,436
12.1c	Age (% of 12.1a; sums to 100%)					
	18-64	34.9	33.8	34.1	34.0	32.2
	65+	65.0	66.2	65.9	66.0	67.8
12.1d	Female (% of 12.1a)	47.0	47.4	49.6	48.5	46.9
12.1e	Race (% of 12.1a; sums to 100%)					
	African American	28.5	29.4	29.3	29.3	37.0
	Asian/Pacific Islander	5.9	5.9	7.8	5.9	4.6
	Native American	3.3	3.0	3.1	3.5	1.2
	White	62.0	61.2	59.2	60.5	56.2
	Other/Unknown/Missing	0.3	0.4	0.5	0.9	1.0
12.1f	Ethnicity (% of 12.1a; sums to 100%)					
	Hispanic	10.2	10.2	10.6	11.6	15.2
	Non-Hispanic	89.8	89.7	89.4	88.3	84.7
	Unknown	0.0	0.0	0.0	0.1	0.1
12.1g	Cause of ESRD (% of 12.1a; sums to 100%)					
	Diabetes	58.2	56.0	56.6	54.9	51.9
	Hypertension	23.7	25.3	24.1	24.6	28.8
	Glomerulonephritis	5.2	4.7	5.0	4.9	4.3
	Other	12.7	13.8	14.1	15.2	14.6
	Unknown/Missing	0.2	0.2	0.2	0.4	0.4
12.1i	Years since start of ESRD (% of 12.1a; sums to 100%)					
	< 1	22.6	21.9	20.2	21.9	20.6
	1-2	14.5	15.8	14.9	16.3	15.4
	2-3	12.8	11.6	13.2	11.7	12.3
	3-6	25.5	26.0	24.2	24.8	25.5
	6+	24.6	24.7	27.5	25.2	26.2
12.1k	Modality (% of 12.1a; sums to 100%)					
	In-center hemodialysis	94.1	93.7	92.5	92.1	90.2
	Home hemodialysis	2.4	3.2	4.4	5.2	7.1
	Continuous ambulatory peritoneal dialysis	0.2	0.1	0.3	0.3	0.2
	Continuous cycling peritoneal dialysis	2.4	2.1	2.2	1.8	1.9
	Other modality	0.9	0.9	0.6	0.7	0.7

(continued)

**TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Characteristics of New Dialysis Patients</b>						
12.2a	Total number of patients with forms (n)	450	420	428	428	23,971
12.2g	Medical coverage (% of 12.2a; sums to 100%)					
	Employer group only	3.1	2.7	2.2	2.7	2.4
	Medicare (alone or combined w/ other insurance)	79.6	83.0	81.3	82.7	82.4
	Medicaid only	11.4	9.8	12.1	10.1	9.8
	Other/Unknown/None	5.9	4.6	4.4	4.5	5.4
12.2k	Number of incident hemodialysis patients (n)	459	430	439	438	24,505
12.2l	Access used at first outpatient dialysis (% of 12.2k; sums to 100%)					
	Arteriovenous fistula	6.2	8.1	7.4	7.3	6.3
	Arteriovenous graft	1.7	1.9	1.9	2.0	2.5
	Catheter	90.1	87.7	88.0	88.1	88.5
	Other/Unknown/Missing	2.1	2.3	2.7	2.5	2.7
12.2m	Arteriovenous fistulae placed (% of 12.2k)	15.8	16.9	16.7	16.0	13.3
12.2s	Pre-ESRD nephrologist care (% of 12.2a; sums to 100%)					
	No	19.4	18.6	14.6	18.5	16.4
	Yes, < 6 months	20.4	20.2	22.5	21.3	22.0
	Yes, 6-12 months	17.0	16.2	16.4	16.0	15.8
	Yes, > 12 months	24.8	25.0	26.6	24.5	20.2
	Unknown	18.4	19.8	19.8	19.5	25.4
12.2t	Informed of transplant options (% of 12.2a)	83.4	84.9	87.2	68.1	68.8
<b>Mortality summary for all NH dialysis patients</b>						
12.3a	Patients (n)	1,994	1,995	2,033	2,073	142,652
12.3b	Patient-years at risk (n)	1,213.2	1,197.2	1,227.7	1,256.1	74,218.2
12.3c	Deaths (n)	520	495	491	498	31,319
12.3d	Expected deaths (n)	463.7	427.5	407.6	411.3	23,901.9
12.3c/12.3b	Death Rate (per 100 PYs at risk)	40.7	43.9	38.1	39.7	42.2
12.3j	Standardized Mortality Ratio (12.3c/12.3d)	1.02	1.37	1.12	1.20	1.31
12.3e	Withdrawal from dialysis prior to death (% of 12.3c)	31.3	32.3	33.5	33.1	26.3
<b>Hospitalization summary for NH Medicare dialysis patients</b>						
12.4a	Medicare dialysis patients (n)	1,794	1,775	1,812	1,857	126,824
12.4b	Patient-years at risk (n)	1,065.5	1,048.7	1,076.5	1,097.6	64,424.5
12.4g	Total admissions (n)	3,043	2,889	3,140	3,255	196,705
12.4h	Expected total admissions (n)	1,989.8	1,964.4	2,127.7	2,204.2	128,710.3
12.4g/12.4b	Hospitalization Rate (per 100 PYs at risk)	266.2	268.7	266.3	283.7	305.3
12.4i	Standardized Hospitalization Ratio (12.4g/12.4h)	1.52	1.59	1.42	1.47	1.53
	Diagnoses associated with hospitalization (% of 12.4a)					
	Septicemia	22.0	22.3	25.5	23.2	22.6
	Acute myocardial infarction	11.5	11.8	11.8	12.7	11.7
	Congestive heart failure	45.5	47.1	46.3	47.5	45.1
	Cardiac dysrhythmia	34.9	34.5	36.2	33.8	32.1
	Cardiac arrest	4.3	3.4	3.3	3.5	3.8

(continued)

**TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This State				United States
		2021	2022	2023	2024	2024
<b>Comorbidities reported on Medicare claims</b>						
12.11a	Medicare dialysis patients on 12/31 (n)	970	949	980	1,005	59,411
12.11b	Comorbidity (% yes of 12.11a)					
<b>Infections</b>						
	AIDS/HIV positive	1.2	0.8	0.7	0.9	1.1
	Intravascular/implanted device-related	7.2	8.3	9.2	8.2	8.2
	Hepatitis B	1.0	0.6	0.6	0.6	0.8
	Hepatitis other	2.8	2.7	2.6	2.3	2.8
	Metastatic	4.1	4.4	4.1	4.4	4.6
	Pneumonia	8.5	8.7	8.9	9.0	10.6
	Tuberculosis	0.3	0.3	0.3	0.2	0.3
	Other	39.3	37.7	39.5	38.3	41.2
<b>Cardiovascular</b>						
	Cardiac arrest	2.5	2.0	2.1	1.9	2.5
	Cardiac dysrhythmia	36.8	36.5	40.1	37.5	39.7
	Cerebrovascular disease	18.4	17.4	17.8	17.6	20.1
	Congestive heart failure	51.6	53.5	55.9	53.9	57.6
	Ischemic heart disease	44.5	43.4	45.5	42.8	46.8
	Myocardial infarction	16.0	13.8	15.4	14.6	16.4
	Peripheral vascular disease	33.7	33.1	35.3	33.2	36.9
<b>Anemia</b>						
12.7b	Eligible adult HD patient-months (n) <sup>*C</sup>	13,050	12,841	13,178	13,423	751,709
12.7d	Hemoglobin (HD) < 10 g/dL (% of 12.7b)	29.4	29.2	29.2	29.3	30.9
12.7e	ESA prescribed (% of 12.7b)	77.4	78.1	80.1	80.5	81.5
12.7f	Eligible adult PD patients (n)	83	81	84	84	4,619
12.7g	Eligible adult PD patient-months (n) <sup>*C</sup>	483	459	482	489	27,372
12.7i	Hemoglobin (PD) < 10 g/dL (% of 7g)	27.0	26.8	28.5	25.6	28.0
12.7j	ESA prescribed (% of 7g)	56.4	55.7	56.9	54.2	55.6
<b>Dialysis Adequacy</b> <sup>*2</sup>						
12.8b	Eligible adult HD Kt/V patient-months (n) <sup>*C</sup>	12,426	12,225	12,585	12,742	713,577
12.8j	Kt/V (HD) < 1.2 (% of 12.8b)	2.5	2.3	2.1	2.1	2.2
12.8k	Eligible adult PD Kt/V patients (n)	83	81	84	84	4,619
12.8l	Eligible adult PD Kt/V patient-months (n) <sup>*C</sup>	483	459	482	489	27,372
12.8n	Kt/V (PD) < 1.7 (% of 12.8l)	9.8	8.3	8.6	8.7	8.7
<b>Vascular Access</b> <sup>*3</sup>						
12.10b	Prevalent adult hemodialysis patient months (n) <sup>*C</sup>	13,630	13,369	13,350	13,482	754,979
12.10c	Arteriovenous fistula in use (% of 12.10b)	49.7	47.9	48.2	48.0	48.3
12.10e	Long-Term Catheter Rate (LTCR)	21.6	22.7	22.6	23.6	23.0

n/a = not applicable; Kt/V: K = dialyzer clearance of urea; t = dialysis time; V = patient's total body water.

[\*1] See *Guide, Section XVI* for detailed information regarding the summaries included in Table 12.

[\*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of *Guide* titled "Determination of Thrice Weekly Dialysis" for more information. PD Kt/V summaries select the most recent value collected within 4 months of the reporting month.

[\*3] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded. Other or missing access types are counted as catheter in use in the numerator. LTCR includes patients using a catheter continuously for three months or longer.

## Appendix: Table Footnotes

This appendix provides information that applies to multiple tables.

[\*A] This value is the ratio of observed events to expected events.

[\*B] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value  $\geq 0.05$  indicates that the ratio is  $>1.05$  or  $<0.95$  plausibly due to random chance.

[\*C] A patient may be counted up to 12 times per year.

SAMPLE